Macular degeneration is the leading cause of vision loss in the elderly.

macular degeneration vitamins have been proven to slow the progression of diseaseVitamin Science, Inc is based in Huntington, New York, and manufactures VisiVite vitamin supplements to treat macular degeneration that are based upon the recommendations of the National Eye Institute, which is part of the United States National Institutes of Health.

These recommendations were based upon multi-year studies involving thousands of patients with macular degeneration. The studies were called the Age Related Eye Disease Study (AREDS) and Age Related Eye Disease Study 2 (AREDS2). Patients with moderate degrees or more of macular degeneration were found to have a reduced rate of progression of their eye disease if they took the high-dose supplements in the study.

These doses were much higher than are typically found in any multi-vitamins, such as Centrum or even prior formulations of eye vitamins, such as Ocuvite or ICaps.

Vitamin Science products are available and/or described on the following sites:

Vitamin Science manufacturers several formulations of VisiVite which are based upon the AREDS and AREDS 2 studies:

  1. VisiVite Original Formula - duplicates the AREDS formula
  2. VisiVite AREDS 2 Gold Formula - Best Seller. Includes Lutein, Zeaxanthin, Zinc, and multiple additional antioxidants, including Vitamin B6, Bilberry, L-glutathione, and Selenium.
  3. VisiVite AREDS 2 Select Formula - includes Lutein, Zeaxanthin and Zinc.
  4. VisiVite AREDS 2 White Formula - Zinc-free AREDS 2 Formula

Important Facts About  Macular Degeneration & Low Vision

Age-related macular degeneration is an eye condition in which the macula, located in the part of the retina responsible for central and detail vision, is damaged, often causing loss of middle vision.

TYPES: "Dry" or Atrophic Form - usually progresses slowly and causes central vision loss. "Wet" or Exudative Form - rarer, and more severe. May progress rapidly causing significant central vision loss.

WHO GETS IT: It is most common in people over 60, but can appear as early as age 40, and is the       most common cause of severe vision loss among people over 65. As life expectancy increases, the disease is becoming an increasingly significant problem.

CAUSES: Heredity is now believed to play an important part, as are the same factors that cause cardiovascular disease.

TREATMENT: There is usually no treatment for the "dry" form, but low vision rehabilitation can help those with significant vision loss to maintain an excellent quality of life. Intraocular medications including Eyelea, Lucentis and Avastin that are injected into the eye are used to treat the wet form of macular degeneration.

CURRENT RESEARCH: There is a great deal of research and several major scientific studies being conducted to find the causes and develop effective treatments. Visit the National Eye Institute Web site for additional information.